

# Meta-analysis of the prognostic value of C-C chemokine receptor type 7 in patients with solid tumors

Guangchen Zu<sup>1,\*</sup>Baoyang Luo<sup>2,\*</sup>Yong Yang<sup>1</sup>Yuwei Tan<sup>1</sup>Tianyu Tang<sup>1</sup>Yue Zhang<sup>1</sup>Xuemin Chen<sup>1</sup>Donglin Sun<sup>1</sup>

<sup>1</sup>Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, People's Republic of China;

<sup>2</sup>Department of Hepatobiliary Surgery, Taizhou People's Hospital, Taizhou 225300, People's Republic of China

\*These authors contributed equally to this work

**Background:** Expression of C-C chemokine receptor type 7 (CCR7) is associated with the prognosis of several cancers. The aim of this study was to conduct the meta-analysis to determine the prognostic value of CCR7 expression in solid tumors.

**Materials and methods:** We searched for relevant literature in the PubMed, Embase, and Cochrane Library databases (last updated on January 15, 2018). The associations of CCR7 expression with overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), progress-free survival (PFS), and disease-specific survival (DSS) were estimated.

**Results:** In total, 30 qualified studies including 3,413 patients were enrolled. The results revealed that higher expression of CCR7 predicted poorer OS (pooled HR =1.79; 95% CI =1.49–2.16;  $P < 0.001$ ) and PFS (pooled HR =2.18; 95% CI =1.49–3.18;  $P < 0.001$ ), but was not associated with DFS (pooled HR =1.69; 95% CI =0.79–3.61;  $P = 0.175$ ), RFS (pooled HR =1.29; 95% CI =0.48–3.44;  $P = 0.618$ ), or DSS (pooled HR =3.06; 95% CI =0.38–24.83;  $P < 0.294$ ).

**Conclusion:** From this meta-analysis, we concluded that high expression of CCR7 in tumor tissue is associated with poor survival in patients with solid tumors, and may be a prognostic biomarker for tumor progression.

**Keywords:** CCR7, solid tumors, prognosis, systematic review, meta-analysis

## Introduction

Cancer remains a worldwide medical problem, and has seriously threatened human health. In 2016, there were ~1.7 million new cancer cases in the USA, and about 0.6 million cancer-related deaths.<sup>1</sup> Although the number of cancer survivors are increasing because of early diagnosis and treatment, traditional diagnostic and therapeutic approaches still cannot control cancer progression and development.<sup>2</sup> Thus, further evidence-based resources for cancer diagnosis are needed so that cancer patients' prognoses can be determined early and precisely.

Chemokines are a class of small molecule proteins that bind to the corresponding cell surface receptors and participate in a variety of physiological, pathological, and immunological processes. Nearly 50 genes in humans encode chemokine ligands and >20 corresponding chemokine receptors. Chemokines can be divided into four categories based on structural differences: CXC, CC, CX3C, and C.<sup>3</sup> Recently, CXC chemokines and their receptors have aroused widespread attention in the field of tumor biology. Müller et al first reported the abnormal expression of C-C chemokine receptor type 7 (CCR7, a member of the C-C chemokine receptor family) in breast cancer.<sup>4</sup> CCR7 is the major receptor for chemokine C ligand 19 (CCL19) and chemokine C

Correspondence: Xuemin Chen; Donglin Sun  
Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Soochow University, No. 185, Juqian Street, Changzhou 21300, People's Republic of China  
Tel +86 138 1358 7333; +86 135 0611 9453  
Email tomuer@126.com; czsdl@sina.com

ligand 21 (CCL21).<sup>5,6</sup> It is mainly expressed on B cells, naive T cells, memory T cells, and mature dendritic cells. The binding between CCR7 and CCL19/CCL21 is vital for lymphocyte cell trafficking and homing to lymph nodes.<sup>7,8</sup> CCR7 is also highly expressed by various malignant tumors, and contributes to biological processes such as tumor cell proliferation,<sup>9</sup> invasion, metastasis,<sup>10</sup> and angiogenesis.<sup>11</sup> Thus, it may promote tumor progression and worsen patients' prognoses.

Elevated CCR7 expression has been associated with poor prognosis in patients with gastric cancer,<sup>12</sup> esophageal squamous cell carcinoma (ESCC),<sup>13</sup> pancreatic cancer,<sup>14</sup> and renal cell carcinoma.<sup>15</sup> However, some studies have revealed no significant association between CCR7 expression and the outcomes of cancers like breast cancer<sup>16</sup> and squamous cell carcinoma of the head and neck (SCCHN).<sup>17</sup> In fact, in colorectal cancer<sup>18</sup> and lung cancer,<sup>19</sup> higher CCR7 expression has been found to predict better prognosis. Therefore, the prognostic value of CCR7 in cancer patients remains unclear. We conducted this systematic review and meta-analysis to further define the relationship between the expression of CCR7 and the survival outcomes of cancer patients.

## Materials and methods

The guidelines of the PRISMA<sup>20</sup> were followed in this meta-analysis.

### Search strategy

We carefully search for literature in PubMed, Embase, and the Cochrane Library (last updated on January 15, 2018). Key terms used in the search were "CCR7", "C-C chemokine receptor type 7", "receptors", "cancer", "tumor", "neoplasm", "carcinoma", "survival", "outcome", "prognosis", and "prognostic". These key terms were combined by the Boolean operators "OR" and "AND". Advanced limitations were not imposed during the database search. We also manually screened the reference lists of the full-text studies to avoid the possible omission of applicable studies. Two authors (Zu G. and Luo B.) independently conducted the exhaustive research.

### Inclusion and exclusion criteria

Manuscripts were considered to be eligible for inclusion in this meta-analysis if they met the following criteria: 1) solid tumors were evaluated; 2) the expression of CCR7 was measured in tumor tissue; 3) the relationship between CCR7 levels and patients' survival outcomes was investigated; and 4) sufficient data were provided to determine the HR and 95% CI. Articles were excluded according to the following

criteria: 1) case reports, reviews, letters, comments, conference abstracts, and experimental studies; 2) investigation of multiple factors rather than CCR7 alone; and 3) lack of key information on patients' survival outcomes, or lack of valid/sufficient data with which to estimate the HR and 95% CI. Two reviewers independently carried out the enrollment and exclusion based on the above criteria, and any disagreement was resolved by discussion.

### Quality assessment

We evaluated the quality of each study according to the critical review checklist of the Dutch Cochrane Center proposed by the Meta-analysis of Observational Studies in Epidemiology group.<sup>21</sup> The main standards were: 1) sufficient report on the study population and the cancer; 2) clear methods of study design; 3) explicit definition of outcome assessment; 4) detailed description of CCR7 measurement; and 5) sufficient period of follow-up. Studies that failed to meet these five standards were excluded.

### Data extraction

Two researchers independently extracted valid data and related information from the eligible studies. Relevant parameters included the first author's surname, publication year, population origin, tumor type, tumor stage, sample number, detection method, follow-up period, sample collection time, cutoff values, and HRs of CCR7 expression for overall survival (OS), disease-free survival (DFS), progress-free survival (PFS), recurrence-free survival (RFS), and disease-specific survival (DSS), and the corresponding 95% CI and *P*-value. If a study reported the results of both univariate and multivariate analyses, the latter was selected because it accounts for confounding factors.

### Statistical analysis

CCR7 levels were defined based on the cutoff value provided in each article. We used the HRs and 95% CIs to calculate the pooled data, and thus evaluated the influence of elevated CCR7 levels on patients' prognoses. Statistical significance was defined as  $P < 0.05$ . The *Q* test and *I*<sup>2</sup> statistic were used to evaluate heterogeneity. If  $P < 0.05$  or  $I^2 > 50\%$ , indicating the existence of heterogeneity, a random-effects model was used, while a fixed-effects model was used when  $P \geq 0.05$  or  $I^2 \leq 50\%$ . Sensitivity, subgroup, and meta-regression analyses were used to explore the potential sources of heterogeneity. Publication bias was analyzed with a funnel plot and Begg's and Egger's tests. We used Stata version 12.0 (StataCorp LP, College Station, TX, USA) to carry out all these analyses.

## Results

### Study characteristics

Using the search strategy described in the section “Materials and Methods”, we initially collected 1,482 articles. After screening the titles, abstracts, and full texts of all the publications, we deemed 109 records eligible for full-text review. Of these, 79 full-text articles were excluded for having insufficient data. Thus, 30 qualified articles were enrolled in this meta-analysis<sup>12–19,22–43</sup> (Figure 1).


The main characteristics of the included studies are summarized in Table 1. The 3,413 patients included in these studies had been diagnosed with ESC, gastric cancer, breast cancer, non-small-cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, epithelial ovarian carcinoma, cervical cancer, etc. The studies included 3,237 patients with OS data, 406 patients with DFS data, 261 patients with RFS data, 192 patients with PFS data, and 203 patients with DSS data, who were from People’s Republic of China, Japan, Germany, France, USA, UK, Austria, and Korea. Twenty-two studies (73%) reported on Asians, and eight studies (27%) reported on Caucasians. HRs and 95% CIs were reported directly in ten studies. CCR7 expression in tumor tissues was measured by immunohistochemistry in all 30 studies, although the cutoff values differed among these studies.

### CCR7 and OS

OS data were reported in 28 of the studies.<sup>12–19,22–41</sup> The detailed results of the meta-analysis are listed in Table 2. As the meta-analysis results exhibited obvious heterogeneity

( $I^2=67.8\%$ ;  $P=0.000$ ), we used a random-effects model to calculate the pooled HR. Higher expression of CCR7 was associated with significantly poorer OS (pooled HR =1.79; 95% CI =1.49–2.16;  $P<0.001$ ) (Figure 2).

We then carried out subgroup analyses according to tumor type, tumor source, patient ethnicity, analysis type, and HR acquisition method; the detailed data are listed in Table 2. Due to the obvious heterogeneity in each group, we used random-effects models to calculate the pooled HRs and 95% CIs. The forest plot of the study-specific pooled HRs and 95% CIs for OS according to tumor type is shown in Figure 3. Higher expression of CCR7 predicted poorer OS in patients with ESC (pooled HR =2.21; 95% CI =1.74–2.82;  $P<0.001$ ) and gastric cancer (pooled HR =1.99; 95% CI =1.58–2.51;  $P<0.001$ ), but was not significantly associated with OS in patients with breast cancer (pooled HR =1.24; 95% CI =0.94–1.62;  $P=0.123$ ), lung cancer (pooled HR =0.89; 95% CI =0.29–2.71;  $P=0.841$ ), or colorectal cancer (pooled HR =0.92; 95% CI =0.20–4.30;  $P=0.919$ ). We also performed a subgroup analysis to evaluate the influence of the tumor source on OS. In patients with tumors of the digestive system and urogenital system, higher CCR7 levels were associated with poorer OS, with pooled HRs of 1.89 (95% CI =1.50–2.38;  $P<0.001$ ) and 2.42 (95% CI =1.87–3.13;  $P<0.001$ ), respectively (Table 2). Remarkably, in the subgroup analysis according to ethnicity, higher CCR7 levels were associated with significantly poorer OS in Asian patients (pooled HR =1.89; 95% CI =1.56–2.29;  $P<0.001$ ), but not in Caucasian patients (pooled HR =1.53; 95% CI =0.89–2.62;  $P=0.121$ ) (Table 2).



**Figure 1** Flowchart of the study selection process.

**Table 1** Main characteristics of the included studies

Study ID	Year	Country	Cancer	Number	Tumor stage (I/II/III/IV)	Sample	Assay	Cutoff value	Multivariate analysis	Survival	HR	Follow-up (months)
Irino et al <sup>13</sup>	2014	Japan	ESC	105	52/53 (I-II/III)	Tissue	IHC	IRS > 1	No	OS	SC	Up to 60
Ding et al <sup>22</sup>	2003	Japan	ESC	96	50/46 (I-II/III-IV)	Tissue	IHC	IRS ≥ 8	No	OS	SC	Up to 100
Shi et al <sup>23</sup>	2015	People's Republic of China	ESC	153	I-III	Tissue	IHC	IRS ≥ 8	No	OS	SC	Up to 60
Liu et al <sup>24</sup>	2013	People's Republic of China	ESC	184	I-III	Tissue	IHC	IRS ≥ 3	No	OS	R	Median 48.6
Song et al <sup>25</sup>	2011	People's Republic of China	ESC	174	122/62 (I-II/III)	Tissue	IHC	>10% of cells stained	Yes	OS	SC	Up to 33
Liu et al <sup>26</sup>	2010	People's Republic of China	Breast	200	177/23 (I-II/III-IV)	Tissue	IHC	IRS ≥ 6	No	OS	SC	Median 88
Andre et al <sup>27</sup>	2006	France	Breast	142	93/49 (I-II/III)	Tissue	IHC	IRS ≥ 3	Yes	OS, DFS	R	Median 156
Cabioglu et al <sup>16</sup>	2007	USA	IBC	44	44 (III)	Tissue	IHC	>50% of cells stained	No	OS	SC	Median 46.5
Sun et al <sup>28</sup>	2015	People's Republic of China	NSCLC	90	39/51 (I-II/III-IV)	Tissue	IHC	IRS ≥ 6	No	OS	SC	Median 32.5
Itakura et al <sup>19</sup>	2013	Japan	Lung	120	69/51 (I-II/III-IV)	Tissue	IHC	Median	No	OS, RFS	R	NR
Günther et al <sup>29</sup>	2005	Germany	Colorectal	99	40/59 (I-II/III-IV)	Tissue	IHC	IRS ≥ 1	No	OS	R	Median 64
Schimanski et al <sup>18</sup>	2005	Germany	Colorectal	96	46/50 (I-II/III-IV)	Tissue	IHC	IRS ≥ 2	No	OS	SC	Up to 36
Zhou et al <sup>12</sup>	2013	People's Republic of China	Gastric	133	50/83 (T1-2/T3-4)	Tissue	IHC	Mean	Yes	OS	SC	Median 43
Ishigami et al <sup>30</sup>	2007	Japan	Gastric	224	120/124 (I-II/III-IV)	Tissue	IHC	Mean	No	OS	R	Up to 60
Ma et al <sup>31</sup>	2015	People's Republic of China	Gastric	122	61/61 (0-III-IV)	Tissue	IHC	>50% of cells stained	No	OS	R	Up to 125
Zhang et al <sup>32</sup>	2015	People's Republic of China	Gastric	90	29/61 (I-II/III-IV)	Tissue	IHC	>50% of cells stained	Yes	OS	R	Median 25
Deguchi et al <sup>33</sup>	2010	Japan	Gastric	72	46/36 (T1-2/T3-4)	Tissue	IHC	NR	No	OS	SC	Up to 120
Kwak et al <sup>34</sup>	2005	Korea	Gastric	307	190/117 (I-II/III-IV)	Tissue	IHC	Moderate staining	No	OS	SC	Median 67
Mashino et al <sup>35</sup>	2002	Japan	Gastric	64	44/20 (I-IIa/IIb-IV)	Tissue	IHC	Strongly/weakly stained	No	OS	SC	Median 21.5
Xia et al <sup>15</sup>	2017	People's Republic of China	MRCC	110	51/59 (I-II/III-IV)	Tissue	IHC	NR	Yes	OS, PFS	R	Median 23.5 (OS), 9.8 (PFS)
Cheng et al <sup>36</sup>	2015	People's Republic of China	EOC	30	12/18 (I-II/III-IV)	Tissue	IHC	IRS ≥ 4	Yes	OS	SC	Median 32
Kodama et al <sup>37</sup>	2007	Japan	Cervical	174	92/82 (IB-IIB)	Tissue	IHC	>50% of cells stained	No	OS, DFS	SC	Median 56.5
Pitkin et al <sup>38</sup>	2007	UK	Tonsillar	84	36/48 (I-II/III-IV)	Tissue	IHC	>33% of cells stained	No	OS, RFS, DSS	SC	Median 33
Xia et al <sup>39</sup>	2015	People's Republic of China	OSSC	60	36/24 (I-II/III-IV)	Tissue	IHC	Median	Yes	OS	SC	Up to 80
Tsuzuki et al <sup>40</sup>	2006	Japan	OOSCC	90	29/61 (I-II/III-IV)	Tissue	IHC	>33% of cells stained	Yes	OS, DFS	SC	30-60
Mburu et al <sup>17</sup>	2012	USA	SCCHN	47	13/30 (I-II/III-IV) 4 (unstaged)	Tissue	IHC	Median	Yes	OS, PFS	R	Up to 120
Kühnelt-Leddihn et al <sup>41</sup>	2012	Austria	PCM	38	NR	Tissue	IHC	NR	No	OS, PFS	SC	Up to 120 (OS), 60 (PFS)
Nakata et al <sup>14</sup>	2008	Japan	Pancreatic	89	82/7 (I-II/III-IV)	Tissue	IHC	Strongly/weakly stained	Yes	OS	R	Up to 120
von Hardenberg et al <sup>42</sup>	2014	Germany	UCB	119	45/74 (T1-2/T3-4)	Tissue	IHC	IRS ≥ 2	No	DSS	R	Median 31
Zhou <sup>3</sup>	2013	People's Republic of China	UCB	57	23/34 (T1-2/T3-4)	Tissue	IHC	IRS ≥ 4	No	RFS	SC	Median 43

**Abbreviations:** DFS, disease-free survival; DSS, disease-specific survival; EOC, epithelial ovarian carcinoma; ESC, esophageal squamous cell carcinoma; IBC, inflammatory breast cancer; IHC, immunohistochemistry; IRS, immunoreactivity score; MRCC, metastatic renal cell carcinoma; NR, not reported; NSCLC, non-small-cell lung cancer; OOSCC, oral and oropharyngeal squamous cell carcinoma; OS, overall survival; OSSC, oral squamous cell carcinoma; PCM, primary cutaneous melanoma; PFS, progress-free survival; R, reported; RFS, recurrence-free survival; SC, survival curve; SCCHN, squamous cell carcinoma of the head and neck; UCB, carcinoma of the bladder.

**Table 2** Pooled HRs and 95% CIs for OS according to subgroup

Subgroup analysis	No. of patients	No. of studies	Random-effects model		Heterogeneity	
			HR (95% CI)	P-value	I <sup>2</sup> (%)	P-value
OS	3,237	28	1.79 (1.49–2.16)	<0.001	67.8	0.000
Ethnicity						
Asian	2,687	21	1.89 (1.56–2.29)	<0.001	63.0	0.000
Caucasian	550	7	1.53 (0.89–2.62)	0.121	77.0	0.000
Tumor type						
ESC	712	5	2.21 (1.74–2.82)	<0.001	0	0.496
Gastric	1,012	7	1.99 (1.58–2.51)	<0.001	0	0.954
Breast	386	3	1.24 (0.94–1.62)	0.123	29.9	0.240
Lung	210	2	0.89 (0.29–2.71)	0.841	92.2	0.000
Colorectal	195	2	0.92 (0.20–4.30)	0.919	92.7	0.000
Other	722	9	2.38 (1.94–2.93)	<0.001	0	0.990
Tumor source						
Digestive system	2,008	15	1.89 (1.50–2.38)	<0.001	55.1	0.005
Urogenital system	314	3	2.42 (1.87–3.13)	<0.001	0	0.766
Other	915	10	1.50 (1.09–2.06)	0.012	68.9	0.001
Analysis type						
Multivariate	965	10	2.12 (1.65–2.73)	<0.001	40	0.091
Univariate	2,272	18	1.63 (1.30–2.06)	<0.001	70.8	0.000
HR acquisition method						
Reported	1,227	10	1.64 (1.12–2.41)	0.012	75.0	0.000
Extrapolated	2,010	18	1.88 (1.52–2.33)	<0.001	64.0	0.000

**Abbreviations:** ESC, esophageal squamous cell carcinoma; OS, overall survival.

## CCR7 and DFS

DFS data were reported by three studies for a total of 406 patients.<sup>27,37,40</sup> As significant heterogeneity was found ( $I^2=74.5\%$ ;  $P=0.020$ ) in this meta-analysis, a random-effects model was used to calculate the pooled HR and 95% CI. The pooled HR was 1.69 (95% CI = 0.79–3.61;  $P=0.175$ ), which indicated that CCR7 expression did not correlate significantly with DFS (Figure 4A).

## CCR7 and PFS

Three studies comprising 192 patients provided valid data for PFS analysis.<sup>15,17,41</sup> We used a fixed effects model to carry out the meta-analysis, as there was no obvious heterogeneity ( $I^2=4.7\%$ ;  $P=0.350$ ). Higher expression of CCR7 was associated with significantly poorer PFS (pooled HR = 2.18; 95% CI = 1.49–3.81;  $P<0.001$ ) (Figure 4B).

## CCR7 and RFS

Three articles including 261 patients provided relevant data for RFS analysis.<sup>19,38,43</sup> As significant heterogeneity was detected ( $I^2=88.4\%$ ;  $P=0.000$ ), we used a random-effects model to calculate the pooled HR. The pooled HR was 1.29 (95% CI = 0.48–3.44;  $P=0.618$ ), which illustrated that higher CCR7 expression tended to portend poorer RFS, but no statistical significance was found (Figure 4C).


## CCR7 and DSS

For DSS, we performed a meta-analysis with two studies.<sup>38,42</sup> A random effects model was used because heterogeneity was identified, and the pooled HR was 3.06 (95% CI = 0.38–24.83;  $P=0.294$ ). The detailed data are described in Figure 4D.

## Heterogeneity analysis

Due to the existence of significant heterogeneity, we performed further analyses to identify potential sources of heterogeneity. First, we conducted a meta-regression analysis, and found that the tumor type ( $P=0.117$ ), patient ethnicity ( $P=0.349$ ), analysis type ( $P=0.172$ ), HR acquisition method ( $P=0.573$ ), sample size ( $P=0.504$ ), publication year ( $P=0.509$ ), follow-up period ( $P=0.091$ ), and cutoff value ( $P=0.444$ ) contributed little to the heterogeneity. We also carried out subgroup analyses to explore the heterogeneity based on tumor type, tumor source, and patient ethnicity. The heterogeneity was still significant in each group (Table 2), indicating that these factors could not solely explain the heterogeneity of the OS analysis.

To evaluate the stability and credibility of the heterogeneity, we performed a sensitivity analysis by omitting individual studies from the OS analysis using a fixed effects model. No individual study obviously impacted the combined HR (Figure 5). We also conducted sensitivity analyses to determine



**Figure 2** Forest plot of studies evaluating the effect of high CCR7 expression on the HR and 95% CI of OS in cancer patients.

**Abbreviations:** CCR7, C-C chemokine receptor type 7; OS, overall survival.

possible factors contributing to the heterogeneity of the DFS and RFS analyses. We found that no single study influenced the result pattern for DFS or RFS (Figure 6A and B).

## Publication bias


We evaluated the possible publication bias of the included studies by using a funnel plot and Egger's test. The funnel plot of the OS analysis is shown in Figure 7. The *P*-value of Egger's regression intercept was 0.339, illustrating that there was no obvious publication bias in this meta-analysis. As the number of studies was not adequate to gain reliable results, we did not carry out publication bias analyses for the DFS, PFS, RFS, or DSS group.

## Discussion

CCR7, one of the seven transmembrane domain G protein-coupled receptors, is the common receptor for chemokines

CCL19 and CCL21.<sup>5,44</sup> They are naturally expressed by various immune cells and secondary lymphoid tissues. The binding of CCR7 to CCL19 and CCL21 induces the lymph-node homing of naive and regulatory T cells and dendritic cells, and promotes the metastasis of these cells to secondary lymphoid organs. The CCR7-CCL19/CCL21 axis regulates various adaptive immune functions, including regulatory and memory T-cell function, secondary lymphoid structure formation, thymocyte genesis, lymphocyte exudation in tumor tissue, high-affinity antigen-antibody immune responses, etc. This signaling axis is also crucial for maintaining the balance between immunity and tolerance.<sup>45-47</sup>

Due to the unique biological function of CCR7 in the immune system, the influence of it on the microenvironment of tumors has attracted widespread academic attention. It is abnormally expressed in a variety of tumors, and contributes to various malignant biological behaviors of tumors,




**Figure 3** Forest plot of studies evaluating the relationship between high CCR7 expression and OS in patients with different cancers.

**Abbreviations:** CCR7, C-C chemokine receptor type 7; ESC, esophageal squamous cell carcinoma; OS, overall survival.


especially, tumor lymph node metastasis. The CCR7-CCL19/CCL21 axis primarily promotes lymph node metastasis by recruiting tumor cells to the T-cell zone of the lymph nodes.<sup>47</sup> The chemotactic interaction between CCR7 and CCL21 has been confirmed as the mechanism for lymph node metastasis in gastric cancer<sup>35</sup> and esophageal cancer.<sup>22</sup> CCR7/CCL21 is also widely recognized to induce lymph node metastasis by upregulating the expression of vascular endothelial growth

factors C and D and further promoting lymphangiogenesis.<sup>28,48,49</sup> Several recent studies have indicated that CCR7 is an important biological marker of tumor lymph node metastasis in many other cancers, including breast cancer,<sup>50</sup> pancreatic cancer,<sup>51</sup> bladder cancer,<sup>52</sup> and head and neck squamous cell carcinoma.<sup>10</sup>

CCR7 is also a key regulator of tumor invasion and distant metastasis. The main regulatory mechanisms are that




**Figure 4** Forest plot of studies evaluating the effects of high CCR7 expression on the HRs and 95% CIs of different survival parameters in cancer patients.  
**Note:** Meta-analysis of (A) DFS; (B) PFS; (C) RFS; and (D) DSS.  
**Abbreviations:** CCR7, C-C chemokine receptor type 7; DFS, disease-free survival; DSS, disease-specific survival; PFS, progress-free survival; RFS, recurrence-free survival.




**Figure 5** Forest plot of sensitivity analysis for OS.  
**Abbreviation:** OS, overall survival.





**Figure 6** Forest plot of sensitivity analysis for **(A)** DFS and **(B)** RFS.  
**Abbreviations:** DFS, disease-free survival; RFS, recurrence-free survival.



**Figure 7** Funnel plot of publication bias for patients' OS.  
**Abbreviation:** OS, overall survival.

1) the CCR7-CCL21/CCL19 axis indirectly facilitates the epithelial-mesenchymal transition by regulating upstream gene expression;<sup>36,53</sup> 2) the CCR7-CCL21/CCL19 axis promotes the expression of matrix metalloproteinases 2 and 9, markers of malignant tumor metastasis and invasion;<sup>54,55</sup> and 3) CCR7 induces phosphatidylinositol-3 kinase/protein kinase B signaling,<sup>56</sup> mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 signaling,<sup>57</sup> and other related signaling pathways that promote tumor invasion

and metastasis. An adequate blood supply is essential for tumor progression, and CCR7 also greatly stimulates tumor angiogenesis, mainly through the following mechanisms: 1) increasing the microvessel density, as part of the CCL21/CCR7 axis in tumor tissues;<sup>11</sup> 2) enhancing the angiogenic capacity and inducing the proliferation and migration of human umbilical vein endothelial cells by activating the nuclear factor  $\kappa$ B pathway;<sup>58</sup> and 3) promoting the expression of vascular endothelial growth factor C in tumor tissues.<sup>59</sup> In

addition, CCR7 has been reported to prevent apoptosis and induce proliferation by promoting G2/M phase progression via the extracellular signal-regulated kinase pathway in human NSCLC.<sup>9,60</sup> Moreover, CCR7 can downregulate interferon  $\gamma$ -induced inflammatory gene expression to weaken the host's antitumor immunity,<sup>61</sup> thus facilitating cancer cell dissemination.<sup>44</sup> Therefore, CCR7 overexpression in the tumor microenvironment is important for cancer progression and is associated with poor prognoses in cancer patients.

Although several studies have shown that CCR7 is a reliable indicator for the prognosis of tumor patients, the effect of CCR7 on the OS of tumor patients remains controversial. Different studies have had the opposite results, even regarding the OS of patients with the same tumor type, such as colorectal cancer<sup>23,24</sup> or lung cancer.<sup>19,28</sup> In addition, CCR7 has been reported to have no significant effect on OS in some tumor types, such as gastric cancer,<sup>33,35</sup> breast cancer,<sup>16,27</sup> and SCCHN.<sup>17</sup> We found that the relationship between CCR7 and the prognosis of various tumors had not been systematically reviewed and further evaluated. Thus, we conducted this meta-analysis to provide a reliable evidence-based medical resource on the prognostic value of CCR7. In total, 30 studies encompassing 3,413 patients with 15 different types of tumors were enrolled in our meta-analysis, and five survival parameters (OS, PFS, RFS, DFS, and DSS) were analyzed. Through this meta-analysis, we provided strong evidence that higher expression of CCR7 is an independent prognostic indicator of poorer OS in patients with solid tumors. Elevated CCR7 levels were also associated with significantly worse PFS; however, there were not sufficient data to confirm that CCR7 was associated with DFS, RFS, or DSS.

To further evaluate the prognostic value of CCR7 in different tumors, we conducted subgroup analyses for OS. Due to the limited number of available articles, we did not carry out subgroup analyses for DFS, RFS, PFS, or DSS. We found that the upregulation of CCR7 significantly shortened the OS of patients with esophageal cancer and gastric cancer. In addition, overexpression of CCR7 tended to predict worse OS in breast cancer patients, but this impact was not notable. Remarkably, CCR7 had the opposite effect on patients with lung cancer and colorectal cancer, as higher CCR7 expression tended to be associated with a better prognosis; however, the results were not statistically significant. For these results, we cannot exclude the impact of insufficient sample sizes and limitations of the studies. We also found that CCR7 was a negative prognostic factor for OS in patients with digestive system and urogenital system tumors. In other systems, however, the relationship between CCR7 expression and tumor prognosis was not clear, suggesting that larger sample sizes and prospective studies are

needed to further investigate the clinical prognostic value of CCR7 according to the tumor source.

We also explored the influence of CCR7 on the OS of patients from different ethnic backgrounds. Patients were categorized as Asian or Caucasian according to the country in which the study was conducted. Different combined HRs and *P*-values for OS were found in Asian and Caucasian patients: the association of high CCR7 expression with poor OS was more significant for Asian patients than for Caucasians. This suggests that racial differences may be an objective factor influencing the survival rate of tumor patients.

Although this meta-analysis confirmed the tumor prognostic value of CCR7, the limitations of this study should still be acknowledged. First, only 30 studies were enrolled in this meta-analysis, so there was a lack of relevant data for correlative and subgroup analyses. Second, the cutoff value for CCR7 expression was not uniform across the studies, which may reduce the effectiveness of CCR7 as a tumor prognostic marker. Third, some of the HR values were extracted from survival curves, which inevitably produced small statistical errors. Finally, this meta-analysis exhibited significant heterogeneity, which could be attributed to several factors, such as the tumor type, analysis method, sample source, cutoff value, follow-up period, and publication year.

In summary, our meta-analysis has suggested that in most solid malignancies, higher expression of CCR7 is associated with poorer prognoses of patients. Although elevated CCR7 expression tended to predict better prognoses in patients with lung cancer and colorectal cancer, these results need to be further confirmed due to their lack of statistical significance. Thus, we can conclude that CCR7 is a reliable, valuable prognostic marker in cancers. In view of the limitations of the current research, this conclusion should be interpreted cautiously. It will be necessary to design large, high-quality, multicenter, prospective clinical trials to confirm the potential value of CCR7 for the prognostic determination, clinical diagnosis, and treatment of tumor patients.

## Author contributions

GZ and BL contributed equally to this work. YY and YT designed the research. GZ and BL wrote the manuscript. GZ, BL, YY, and YT collected the relevant papers and data. GZ, BL, YY, and TT analyzed and processed the data. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016;66(1):7–30.
- Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin.* 2016;66(4):271–289.
- Balkwill FR. The chemokine system and cancer. *J Pathol.* 2012;226(2):148–157.
- Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. *Nature.* 2001;410(6824):50–56.
- Ott TR, Pahuja A, Nickolls SA, Alleva DG, Struthers RS. Identification of CC chemokine receptor 7 residues important for receptor activation. *J Biol Chem.* 2004;279(41):42383–42392.
- Willmann K, Legler DF, Loetscher M, et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. *Eur J Immunol.* 1998;28(6):2025–2034.
- Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. *Cancer Res.* 2000;60(8):2209–2217.
- Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. *J Exp Med.* 1998;188(2):373–386.
- Xu Y, Liu L, Qiu X, et al. CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells. *PLoS One.* 2011;6(6):e21119.
- Liu FY, Safdar J, Li ZN, et al. CCR7 regulates cell migration and invasion through JAK2/STAT3 in metastatic squamous cell carcinoma of the head and neck. *Biomed Res Int.* 2014;2014(4):1–11.
- Zhao B, Cui K, Wang CL, et al. The chemotactic interaction between CCL21 and its receptor, CCR7, facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. *J Hepatobiliary Pancreat Sci.* 2011;18(6):821–828.
- Zhou S, Shen Z, Wang Y, et al. CCR7 expression and intratumoral Foxp3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. *PLoS One.* 2013;8(9):e74430.
- Irino T, Takeuchi H, Matsuda S, et al. CC-chemokine receptor CCR7: a key molecule for lymph node metastasis in esophageal squamous cell carcinoma. *BMC Cancer.* 2014;14:291.
- Nakata B, Fukunaga S, Noda E, Amano R, Yamada N, Hirakawa K. Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. *Oncology.* 2008;74(1–2):69–75.
- Xia Y, Liu L, Xiong Y, et al. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. *BMC Cancer.* 2017;17(1):70.
- Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. *Ann Oncol.* 2007;18(6):1021–1029.
- Mburu YK, Eglhoff AM, Walker WH, et al. Chemokine receptor 7 (CCR7) gene expression is regulated by NF- $\kappa$ B and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). *J Biol Chem.* 2012;287(5):3581–3590.
- Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. *Clin Cancer Res.* 2005;11(5):1743–1750.
- Itakura M, Terashima Y, Shingyoji M, et al. High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. *Br J Cancer.* 2013;109(5):1100–1108.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg.* 2010;8(5):336–341.
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. *JAMA.* 2000;283(15):2008–2012.
- Ding Y, Shimada Y, Maeda M, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. *Clin Cancer Res.* 2003;9(9):3406–3412.
- Shi M, Chen D, Yang D, Liu XY. CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1. *J Exp Clin Cancer Res.* 2015;34(1):149.
- Liu XY, Song L, Wang Z. CCR7: a metastasis and prognosis indicator of postoperative patients with esophageal carcinoma. *Hepatogastroenterology.* 2013;60(124):747–750.
- Song L, Wang Z, Liu X, Chen G, Liu F. Expression of CCR7 in squamous cell carcinoma of the esophagus after esophagectomy: correlation with lymph node metastasis and prognosis. *Chin J Thorac Cardiovasc Surg.* 2011;27:361–364.
- Liu Y, Ji R, Li J, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. *J Exp Clin Cancer Res.* 2010;29(1):16.
- Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. *Ann Oncol.* 2006;17(6):945–951.
- Sun L, Zhang Q, Li Y, Tang N, Qiu X. CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells. *Int J Clin Exp Pathol.* 2015;8(12):15729–15738.
- Günther K, Leier J, Henning G, et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. *Int J Cancer.* 2005;116(5):726–733.
- Ishigami S, Natsugoe S, Nakajo A, et al. Prognostic value of CCR7 expression in gastric cancer. *Hepatogastroenterology.* 2007;54(76):1025–1028.
- Ma H, Gao L, Li S, et al. CCR7 enhances TGF- $\beta$ 1-induced epithelial-mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer. *Oncotarget.* 2015;6(27):24348–24360.
- Zhang J, Zhou Y, Yang Y. CCR7 pathway induces epithelial-mesenchymal transition through up-regulation of snail signaling in gastric cancer. *Med Oncol.* 2015;32(2):467.
- Deguchi K, Ichikawa D, Soga K, et al. Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. *Anticancer Res.* 2010;30(6):2361–2366.
- Kwak MK, Hur K, Park DJ, et al. Expression of chemokine receptors in human gastric cancer. *Tumor Biol.* 2005;26(2):65–70.
- Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. *Canc Res.* 2002;62(10):2937–2941.
- Cheng S, Guo J, Yang Q, Yang X. Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas. *Med Oncol.* 2015;32(3):47.
- Kodama J, Hasengaowa, Seki N, Kusumoto T, Hiramatsu Y. Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. *Eur J Gynaecol Oncol.* 2007;28(5):370–375.
- Pitkin L, Luangdilok S, Corbishley C, et al. Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival. *Br J Cancer.* 2007;97(5):670–677.
- Xia X, Liu K, Zhang H, Shang Z. Correlation between CCR7 expression and lymph node metastatic potential of human tongue carcinoma. *Oral Dis.* 2015;21(1):123–131.
- Tsuzuki H, Takahashi N, Kojima A, et al. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. *Auris Nasus Larynx.* 2006;33(1):37–42.
- Kühnelt-Leddihn L, Müller H, Eisendle K, Zelger B, Weinlich G. Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10? *Arch Dermatol Res.* 2012;304(3):185–193.
- von Hardenberg J, Martini T, Knauer A, et al. Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder. *Urol Oncol.* 2014;32(1):54.e9–17.
- Zhou M, Zhang D, Xiaolong Q, Liu F, Lin Q, Xiongbing Z. Significance of CCR7 expression in bladder urothelial carcinoma. *Chin J Urol.* 2013;34(5):352–356.
- Legler DF, Uetz-von Allmen E, Hauser MA. CCR7: roles in cancer cell dissemination, migration and metastasis formation. *Int J Biochem Cell Biol.* 2014;54:78–82.

45. Förster R, Davalos-Miszlitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. *Nat Rev Immunol*. 2008;8(5):362–371.
46. Comerford I, Harata-Lee Y, Bunting MD, Gregor C, Kara EE, McColl SR. A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. *Cytokine Growth Factor Rev*. 2013;24(3):269–283.
47. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. *Nat Rev Immunol*. 2011;11(9):597–606.
48. Tutunea-Fatan E, Majumder M, Xin X, Lala PK. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis. *Mol Canc*. 2015;14(1):35.
49. Song Y, Wang Z, Liu X, Jiang W, Shi M. CCR7 and VEGF-C: molecular indicator of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy? *Ann Surg Oncol*. 2012;19(11):3606–3612.
50. El-Ghonaimy EA, El-Shinawi M, Ibrahim SA, et al. Positive lymph-node breast cancer patients – activation of NF-κB in tumor-associated leukocytes stimulates cytokine secretion that promotes metastasis via C-C chemokine receptor CCR7. *FEBS J*. 2015;282(2):271–282.
51. Guo J, Lou W, Ji Y, Zhang S. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. *Oncol Lett*. 2013;5(5):1572–1578.
52. Chen J, Cui YU, Liu L, et al. CCR7 as a predictive biomarker associated with computed tomography for the diagnosis of lymph node metastasis in bladder carcinoma. *Oncol Lett*. 2016;11(1):735–740.
53. Zhong G, Chen L, Yin R, et al. Chemokine (C-C motif) ligand 21/C-C chemokine receptor type 7 triggers migration and invasion of human lung cancer cells by epithelial-mesenchymal transition via the extracellular signal-regulated kinase signaling pathway. *Mol Med Rep*. 2017;15(6):4100–4108.
54. Guo N, Liu F, Yang L, Huang J, Ding X, Sun C. Chemokine receptor 7 enhances cell chemotaxis and migration of metastatic squamous cell carcinoma of head and neck through activation of matrix metalloproteinase-9. *Oncol Rep*. 2014;32(2):794–800.
55. Mo M, Zhou M, Wang L, et al. CCL21/CCR7 enhances the proliferation, migration, and invasion of human bladder cancer T24 cells. *PLoS One*. 2015;10(3):e0119506.
56. Li K, Xu B, Xu G, Liu R. CCR7 regulates twist to induce the epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. *Tumor Biol*. 2016;37(1):419–424.
57. Liu FY, Safdar J, Li ZN, et al. CCR7 regulates cell migration and invasion through MAPKs in metastatic squamous cell carcinoma of head and neck. *Int J Oncol*. 2014;45(6):2502–2510.
58. Cai QY, Liang GY, Zheng YF, Tan QY, Wang RW, Li K. CCR7 enhances the angiogenic capacity of esophageal squamous carcinoma cells in vitro via activation of the NF-κB/VEGF signaling pathway. *Am J Transl Res*. 2017;9(7):3282–3292.
59. Chi BJ, du CL, Fu YF, Zhang YN, Wang RW. Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC. *Int J Clin Exp Pathol*. 2015;8(10):12533–12540.
60. Xu Y, Liu L, Qiu X, et al. CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells. *PLoS One*. 2012;7(3):e33262.
61. Takekoshi T, Fang L, Paragh G, Hwang ST. CCR7-expressing B16 melanoma cells downregulate interferon-γ-mediated inflammation and increase lymphangiogenesis in the tumor microenvironment. *Oncogenesis*. 2012;1(5):e9.

## Cancer Management and Research

### Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes

a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

Dovepress